Cycloserine in the Treatment of Sleep Apnea

• Status: Terminated
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being conducted to determine whether cycloserine is effective for the treatment of sleep apnea. Cycloserine is an antibiotic that has been extensively used in the treatment tuberculosis. However, more recently it was shown to enhance memory responses. Cycloserine may enhance the response of respiratory muscles to apnea and potentially reduce the severity of sleep disordered breathing.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Manitoba
• Collaborator: University of Calgary
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

• Moderate to severe obstructive or central sleep apnea (Apnea Hypopnea Index > 30/hr).

• Minimum Oxygen saturation during respiratory events >70% throughout sleep during the clinical sleep study.

Exclusion Criteria:

• Contraindication to the use of cycloserine, namely history of allergy to cycloserine, seizures, depression, severe anxiety or psychosis, excessive use of alcohol or renal failure.

• Past or current history of tuberculosis

• Hypercapnia > 55 millimeters of mercury during the diagnostic clinical sleep study.

• Neuromuscular disease.

• Obesity-hypoventilation syndrome.

• Pregnancy.

• Significant co-morbidities: Dialysis-dependant renal failure, severe asthma or chronic lung disease, congestive heart failure, previous stroke.

• Recent (within 3 months) myocardial infarction or Active coronary ischemia event.